Indian pharmaceutical market touches 1,00,000 crore mark

This could be good news for the well-wishers of the Indian pharmaceutical market, since a recent report by IMS Health has revealed that the market has, for the first time, touched the Rs 1,00,000 crore mark. IMS Health is a research firm dealing in the global pharmaceutical market.

The study has shown that the golden landmark was touched in November, and the figure was calculated on the basis of Moving Annual Total (MAT).

In the report, it is said that three-fourth of the market share was taken over by Indian companies during the month of November.

The Indian pharmaceutical market has grown by an average of 12% over the last three years. In this, drugs that treat infections, heart ailments and patients with gastro-intestinal issues covered almost 38% of the share.

As per the report, in November, Indian market was valued at Rs 1,00,115 crore, of which the retail sector was valued at Rs 84,279 crore.

Talking of companies, Sun Pharma held its top position with a market share of 8%, followed by Abbott that has a share of 6.1%. Cipla isn’t too far behind, with 5.4% market share, and has grown higher than its top peers with a growth of 16% during the month.

In brands, however, it was Mixtard, the popular insulin marketed by Abbott, that retained its first position as the largest brand for the month. It was followed by the cough syrup brand Corex (Pfizer) and Glycomet-gp, a diabetes brand of USV.

Image source